US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Athira Pharma, Inc. - Common Stock (NQ:ATHA)

6.750 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Athira Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”
New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Stock Shot Up 60% Today – What’s Triggering The Super Rally? ↗
Athira Pharma secured exclusive rights to a Phase 3 breast cancer drug and announced a $236 million financing package to support its development. 
Via Stocktwits
News headline image
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Announces Reverse Stock Split
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira (ATHA) Q2 Loss Narrows 74% ↗
Via The Motley Fool
News headline image
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical... 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings ↗
 
Via Benzinga
News headline image
US Stocks Mixed; Trade Gap Widens In July ↗
 
Via Benzinga
News headline image
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks ↗
Athira Pharma stock falls as the company reports mixed results from its Phase 2/3 LIFT-AD clinical trial for Alzheimer's treatment fosgonimeton, with data showing directional improvements but no... 
Via Benzinga
News headline image
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024 ↗
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >